Rare diseases
Investigational molecules
Locations
Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn's Disease
PolandStudy on the Effectiveness of Infliximab, Tofacitinib, and Vedolizumab in Patients with Ulcerative Colitis Resistant to Initial Treatment
PolandPhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
FranceLong-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease
BelgiumStudy on Vedolizumab and Ustekinumab for Patients with Crohn's Disease and Ulcerative Colitis
DenmarkStudy on Reducing Vedolizumab Dosage for Patients with Inflammatory Bowel Disease
The NetherlandsTitle: Study of vedolizumab dose adjustment guided by drug level monitoring in patients with inflammatory bowel disease in remission
The NetherlandsStudy on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease
AustriaStudy on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab
The NetherlandsStudy on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn's Disease
BelgiumStudy on the Effectiveness and Safety of Vedolizumab, Budesonide, and Prednisone for Children with Moderate to Severe Crohn's Disease
BelgiumStudy Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis
PolandTell us about your condition – we search every trial in Europe and connect you with the right site.
